Key Takeaways
- FDA approval of oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, is expected in June.
- OLC is positioned as a best-in-class option due to simpler dosing in a therapeutic area where the standard of care is phosphate binders, which have a high pill burden.
- Unicycive only has 26 employees, but the company is ramping up to launch OLC independently.
Unicycive Therapeutics was started by a single person, went public through an IPO in 2021, and four years later is preparing to continue its track record of proving skeptics wrong...
The company is anticipating action from the US Food and Drug Administration on 28 June on a new drug application for oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in chronic...